Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial von Kroiss, Matthias, Quinkler, Marcus, Johanssen, Sarah, van Erp, Nielka P, Lankheet, Nienke, Pöllinger, Alexander, Laubner, Katharina, Strasburger, Christian J, Hahner, Stefanie, Müller, Hans-Helge, Allolio, Bruno, Fassnacht, Martin

Volltext

Clinical pharmacokinetics of tyrosine kinase inhibitors von van Erp, Nielka P, Gelderblom, Hans, Guchelaar, Henk-Jan

Volltext

Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis von Op ’t Hoog, Catharina J. P., Bosman, Sabien J. E., Boerrigter, Emmy, Mehra, Niven, van Oort, Inge M., van Erp, Nielka P., Kievit, Wietske

Volltext

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose von Westerdijk, Kim, Desar, Ingrid M.E., Steeghs, Neeltje, Graaf, Winette T.A., Erp, Nielka P.

Volltext

Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials von Mir, Olivier, Touati, Nathan, Lia, Michela, Litière, Saskia, Le Cesne, Axel, Sleijfer, Stefan, Blay, Jean-Yves, Leahy, Michael, Young, Robin, Mathijssen, Ron H J, Van Erp, Nielka P, Gelderblom, Hans, Van der Graaf, Winette T, Gronchi, Alessandro

Volltext

Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study von Benoist, Guillemette E, van Oort, Inge M, Boerrigter, Emmy, Verhaegh, Gerald W, van Hooij, Onno, Groen, Levi, Smit, Frank, de Mol, Pieter, Hamberg, Paul, Dezentjé, Vincent O, Mehra, Niven, Gerritsen, Winald, Somford, Diederik M, van Erp, Nielka P H, Schalken, Jack A

Volltext

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS von Krens, Stefanie D., Meulen, Eric, Jansman, Frank G.A., Burger, David M., Erp, Nielka P.

Volltext

Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites von Krens, Stefanie D., Mulder, Sasja F., van Erp, Nielka P.

Volltext

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide von Podgoršek, Eva, Mehra, Niven, van Oort, Inge M., Somford, Diederik M., Boerrigter, Emmy, van Erp, Nielka P.

Volltext

mTOR inhibitor‐induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm von Willemsen, Annelieke E.C.A.B., Grutters, Jan C., Gerritsen, Winald R., van Erp, Nielka P., van Herpen, Carla M.L., Tol, Jolien

Volltext

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure von Krens, Stefanie D., Lubberman, Floor J. E., Egmond, Marthe, Jansman, Frank G. A., Burger, David M., Hamberg, Paul, Vervenne, Walter L., Gelderblom, Hans, Graaf, Winette T. A., Desar, Ingrid M. E., Herpen, Carla M. L., Erp, Nielka P.

Volltext

Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer von Krens, Stefanie D, van Erp, Nielka P, Groenland, Stefanie L, Moes, Dirk Jan A R, Mulder, Sasja F, Desar, Ingrid M E, van der Hulle, Tom, Steeghs, Neeltje, van Herpen, Carla M L

Volltext

Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report von Boerrigter, Emmy, Havenith, Thomas, van Erp, Nielka P., Schnog, John-John B.

Volltext

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metast... von Weijers, Jetty A M, Verhaegh, Gerald W, Lassche, G, van Engen-van Grunsven, Adriana C H, Driessen, Chantal M L, van Erp, Nielka P, Jonker, Marianne A, Schalken, Jack A, van Herpen, Carla M L

Volltext

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients von Benoist, Guillemette E., van Oort, Inge M., Burger, David M., Mehra, Niven, van Erp, Nielka P.

Volltext

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity von VAN ERP, Nielka P, EECHOUTE, Karel, GUCHELAAR, Henk-Jan, GELDERBLOM, Hans, VAN DER VELDT, Astrid A, HAANEN, John B, REYNERS, An K. L, MATHIJSSEN, Ron H. J, BOVEN, Epie, VAN DER STRAATEN, Tahar, BAAK-PABLO, Renée F, WESSELS, Judith A. M

Volltext

Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer von Guchelaar, Niels A.D., van Eerden, Ruben A.G., Groenland, Stefanie L., Doorn, Leni van, Desar, Ingrid M.E., Eskens, Ferry A.L.M., Steeghs, Neeltje, van Erp, Nielka P., Huitema, Alwin D.R., Mathijssen, Ron H.J., Koolen, Stijn L.W.

Volltext

Mitotane has a strong and a durable inducing effect on CYP3A4 activity von van Erp, Nielka P, Guchelaar, Henk-Jan, Ploeger, Bart A, Romijn, Johannes A, Hartigh, Jan den, Gelderblom, Hans

Volltext

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients von van Erp, Nielka P., van Herpen, Carla M., de Wit, Djoeke, Willemsen, Annelieke, Burger, David M., Huitema, Alwin D. R., Kapiteijn, Ellen, ter Heine, Rob

Volltext

Dried blood spot analysis for therapeutic drug monitoring of pazopanib von de Wit, Djoeke, den Hartigh, Jan, Gelderblom, Hans, Qian, Yanwen, den Hollander, Margret, Verheul, Henk, Guchelaar, Henk-Jan, van Erp, Nielka P.

Volltext